USA flag logo/image

An Official Website of the United States Government

Near Infrared Semiconductor Nanocrystal for Imaging Guided Surgery

Award Information

Department of Health and Human Services
Award ID:
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
P.O. Box 2168 Fayetteville, AR 72702 2168
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2009
Title: Near Infrared Semiconductor Nanocrystal for Imaging Guided Surgery
Agency: HHS
Contract: 1R43CA141817-01
Award Amount: $170,679.00


DESCRIPTION (provided by applicant): Nanomaterials and Nanofabrication Laboratories Program Announcement No. PA-08-050 (NN-Labs, LLC) Title: Near Infrared Semiconductor Nanocrystal for Imaging Guided Surgery Principal Investigator: Tiecheng Qiao Summary Th e incidence of brain metastasis in patients with melanoma ranges from 10% to 40% and is even higher in autopsy series. Survival rate for patients with stage IV disease is typically measured in months. Surgery is usually recommended for single brain metasta ses in patients with controlled or controllable systemic disease. A complete and aggressive surgical resection should be performed whenever possible followed by post-operative radiation. However, the ability to achieve complete resection (i.e., negative ma rgin) is sometimes limited by the surgeon's ability to distinguish residual tumor from surrounding brain tissue under conventional white-light illumination. To address this technical difficulty, this Phase I project will develop a novel class of near infra red nanoparticles (NIR-NP) for imaging guide surgery (ICG) applications. Such materials are not commercially available today and will provide surgeons an ease of use surgical navigation imaging agent with precision and real time feedback, and overall, impr ove clinical outcome for cancer patients. We will select a tumor targeting peptide that will be attached to the surface of NIR nanoparticles. Tumor bearing mice will be used as a model to show the preferably accumulation of NIR nanoparticles on tumor site. The advantage of using a NIR nanoparticles guided resection of tumor in mice versus simple visual resection will be demonstrated. Criteria for success involve the following requirements: 1. The NIR nanoparticles must be readily dispersible biological beni gn solution, such as phosphate buffer saline solution (PBS), without agglomeration, 2. The NIR nanoparticles must possess good biodistribution and body clearance profile, 3. The NIR nanoparticle must meet, or exceed, clinical requirements. We will evaluate the cytotoxicity and biocompatibility of our NIR-NP through a series of in vitro assays. Ultimately, we will demonstrate the feasibility and benefit of using NIR-NP in IGS over conventional visual surgery in mice model with subcutaneously inoculated B16-B L6 melanoma. 1 PUBLIC HEALTH RELEVANCE: Approximately 1.5 million people in the US are diagnosed with cancer annually; and half of the 1.5 million new cancer cases diagnosed in the U.S. this year will be treated with excision surgery. One common problem as sociated with tumor-related surgical procedures is the difficulty for surgeons to visualize the tumor margin before the operation and to complete the excision of cancerous tissue during surgery. It is estimated that tumor reoccurrence rate could be as high as 20-30% after tumor-excision surgical procedures, and that the subsequent metastasis of unexcised cancerous growth leads to further clinical complications. The goal of this program is to develop an imaging guided surgery system using near infrared nanop articles that would allow surgeons to maximizing tumor removal with minimal peri-tumoral damage to surrounding normal tissue. Near infrared imaging has the potential to improve the intraoperative detection of patients with malignant tumor that surgical res ection is a must procedure. It is anticipated that the reduced costs and higher resolutions will permit more complete tumor resections, more accurate biopsies, and faster procedures with better patient outcomes and lower patient cost and morbidity.

Principal Investigator:

Tiecheng A. Qiao

Business Contact:

Tiecheng Qiao
Small Business Information at Submission:


EIN/Tax ID: 731624630
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No